VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,545,000 | +27.3% | 30,306 | +24.7% | 0.00% | – |
| Q2 2023 | $1,213,542 | -96.3% | 24,300 | -97.2% | 0.00% | -100.0% |
| Q1 2023 | $32,398,087 | -33.6% | 864,410 | -15.1% | 0.01% | -41.7% |
| Q4 2022 | $48,820,676 | +31.6% | 1,018,158 | -34.1% | 0.01% | +33.3% |
| Q3 2022 | $37,094,000 | +43.6% | 1,545,567 | +30.2% | 0.01% | +28.6% |
| Q2 2022 | $25,829,000 | +46.6% | 1,186,986 | +62.7% | 0.01% | +75.0% |
| Q1 2022 | $17,619,000 | +679.3% | 729,555 | +667.5% | 0.00% | – |
| Q4 2021 | $2,261,000 | +51.6% | 95,050 | +61.8% | 0.00% | – |
| Q3 2021 | $1,491,000 | -37.1% | 58,734 | -44.2% | 0.00% | – |
| Q2 2021 | $2,370,000 | +8.3% | 105,297 | -5.0% | 0.00% | -100.0% |
| Q1 2021 | $2,189,000 | -57.7% | 110,837 | -43.1% | 0.00% | 0.0% |
| Q4 2020 | $5,176,000 | +99.5% | 194,811 | +270.7% | 0.00% | 0.0% |
| Q3 2020 | $2,595,000 | -85.1% | 52,559 | -90.4% | 0.00% | -83.3% |
| Q2 2020 | $17,377,000 | – | 549,751 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management, LLC | 22,227 | $439,000 | 0.50% |